Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma

NCT05789394 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05789394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
June 16, 2023
Completion date
July 24, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iv, recurrent astrocytoma, idh-mutant, grade 4, recurrent glioblastoma, idh-wildtype